Study title: Tolerance of Primalan in children (21 days)
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Immune System Diseases [C20] | |||||
Brands: | |||||
MAH holders: | |||||
Assessment: | |||||
Active substance: MEQUITAZINE | |||||
ATC code: | |||||
Document link: Primalan L0013SOC002.xls | |||||
Document date: 2011-09-19 | |||||
Study number: L0013 SO C 002 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | - |